Flt1 - FMS-like tyrosine kinase 1 Gene

Mus musculus

Also known as Flt-1; sFlt1; VEGFR1; VEGFR-1

Gene ID: 14254 | Gene type: protein coding

About Flt1

Chromosome 5: 147,498,414-147,662,821 reverse strand.GRCm39:CM000998.3

This gene has 6 transcripts (splice variants), 199 orthologues, 53 paralogues and is associated with 24 phenotypes. Biased expression in placenta adult (RPKM 35.7), lung adult (RPKM 11.8) and 11 other tissues.

Summary

Enables identical protein binding activity and vascular endothelial growth factor-activated receptor activity. Involved in several processes, including blood vessel morphogenesis; embryonic morphogenesis; and hyaloid vascular plexus regression. Acts upstream of or within several processes, including angiogenesis; positive regulation of hematopoietic progenitor cell differentiation; and post-embryonic camera-type eye morphogenesis. Located in extracellular space and nucleus. Is expressed in several structures, including alimentary system; cardiovascular system; central nervous system; extraembryonic component; and genitourinary system. Human ortholog(s) of this gene implicated in Kuhnt-Junius degeneration; diabetic retinopathy; and pre-eclampsia. Orthologous to human FLT1 (fms related receptor tyrosine kinase 1). [provided by Alliance of Genome Resources, Apr 2022]

Flt1 Products(2)

mRNA	Protein	Name
NM_001363135.1	NP_001350064.1	vascular endothelial growth factor receptor 1 isoform 2 precursor
NM_010228.4	NP_034358.2	vascular endothelial growth factor receptor 1 isoform 1 precursor

Flt1 Protein Structure

Ig_3

IGc2

I-set

PKc_like

0
300
600
900
1200
1333 a.a.

Protein Preferred Names

Protein Names

vascular endothelial growth factor receptor 1

embryonic receptor kinase 2	tyrosine-protein kinase receptor FLT
vascular permeability factor receptor

Recombinant Flt1 Proteins

Cat. No.	Product Name	Accession	Purity
HY-P73553	VEGFR-1 Protein, Mouse (HEK293, His)	P35969/NP_034358.2 (Y23-E759)	≥95%

Related Agents

Clinical Phase

Bioactive Molecules (6)

Cat. No.	Product Name	Effect	Purity	Phase
HY-50751	Linifanib		99.28%	Phase 3
HY-10205	Cediranib		99.58%	Phase 3
HY-10517	Orantinib		99.21%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-50751G	Linifanib (GMP)	Inhibitor	/	Phase 3
HY-10204	OSI-930		98.57%	Phase 1

Inhibitory Antibodies (2)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99830	Conbercept		/	Phase 4
HY-P99364	Icrucumab	Inhibitor	95.00%	Phase 2

Pre-clinical Phase

Bioactive Molecules (9)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-145293	TNIK-IN-3	Inhibitor	99.88%	Unkown
HY-101219	VEGFR-IN-1	Inhibitor	98.42%	Unkown
HY-15813	FIIN-1	Inhibitor	99.11%	Unkown
HY-110272	Vatalanib succinate	Inhibitor	/	Unkown
HY-168114	Multi-kinase inhibitor 3	Inhibitor	/	Unkown
HY-168115	Multi-kinase inhibitor 4	Inhibitor	/	Unkown
HY-RS04987	FLT1 Human Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown
HY-RS04988	Flt1 Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown
HY-RS04989	Flt1 Rat Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Flt1	NCBI	NCBI:2321
Rattus norvegicus	Flt1	NCBI	NCBI:54251

Name
Email *

	Sorry, but the email address you supplied was invalid.